Grand Rounds September 28, 2021 by John Tayek, MD, MS presents “Renal and CV Benefits of DM Medications"
Tue, September 28, 2021 11:00 AM - Tue, September 28, 2021 12:00 PM at ZOOM ONLY
Learning Objectives: At the completion of this activity, participants will be able to:
1. Recognize that SGLT-2 inhibitors reduce CKD progression, MACE, CV events, but not CVAs.
2. Recognize that GLP-1 agents reduce MACE, CV events, CVA and can be given to ESRD patients.
3. Evaluate using SGLT-2 inhibitors to prevent progression of CKD in Diabetics and Non-Diabetic Patients.
4. Identify that pioglitazone reduces carotid plaque and reduces CVAs in Diabetics (PROACTIVE) and Pre- Diabetics (IRIS).